The Longevity Podcast: Optimizing HealthSpan & MindSpan

Inside The Alzheimer’s Maze

Dung Trinh

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 13:58

Send a text

We map how Alzheimer’s disrupts the brain’s wiring, how symptoms progress from memory slips to loss of judgment and orientation, and why ruling out treatable look-alikes can change the story. We also weigh proven medications, cautious new therapies, and the daily practices that protect function and dignity.

• biology of plaques, tangles, and acetylcholine loss
• early, middle, and late symptom patterns
• risks that rise with age, family history, and genes
• diagnosis built on history, cognitive tests, and imaging
• reversible mimics including B12 deficiency and hypothyroidism
• cholinesterase inhibitors and memantine for symptom management
• monoclonal antibodies, potential benefits, and MRI-monitored risks
• lifestyle strategies: exercise, cognitive activity, Mediterranean-style diet
• caregiver playbook: familiar routines, safe home, music and art engagement


This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.

Never miss an episode—subscribe on your favorite podcast app!

Setting The Mission

SPEAKER_01

Welcome to the deep dive. Today we're tackling a subject that is often incredibly complex and for many deeply personal, Alzheimer's disease.

SPEAKER_00

Aaron Ross Powell It really is.

SPEAKER_01

We've pulled our information from some crucial, very detailed source material from experts at Harvard Health because we know you want to approach this with real knowledge, but without getting lost in all of the medical jargon.

Biology Of Alzheimer’s

SPEAKER_00

Aaron Powell That's right. And our goal for this deep dive is well, it's pretty clear. We want to move beyond just the basic definition. We're going to try and unpack the biological progression of Alzheimer's or AD and uh clarify the diagnostic methods, which can be tricky.

SPEAKER_01

Aaron Powell And then get into the really current stuff, the treatment and prevention strategies that are evolving so quickly.

SPEAKER_00

Exactly.

SPEAKER_01

So AD is the most common form of dementia. Our sources define it as an irreversible loss of brain functions that just gets progressively worse over time. It typically starts after age 60, but what is actually happening inside the brain to trigger this collapse?

SPEAKER_00

Aaron Powell At its core, it's a tragedy of communication failure within the brain. The very first function that's almost always affected is short-term memory.

SPEAKER_01

Aaron Powell That mental filing system you use every minute.

SPEAKER_00

Aaron Ross Powell Exactly that. The one that lets you recall what you just heard or where you put your keys a second ago. As that starts to erode, it um it gradually impairs other intellectual abilities.

SPEAKER_01

Aaron Powell So things like language, problem solving.

SPEAKER_00

Trevor Burrus Yes. And eventually it leads to severely impaired judgment.

SPEAKER_01

Aaron Powell So we know the result is this intellectual failure, but let's dig into the biology. What's the cause of this system-wide failure? The sources seem to point to both a physical and a chemical breakdown.

SPEAKER_00

Aaron Powell Absolutely.

SPEAKER_01

Yeah.

SPEAKER_00

And what makes AD such a well such a challenging puzzle is that we don't have one single undisputed trigger. What researchers have identified, though, are two primary culprits. Two proteins? Two proteins that start accumulating in, frankly, toxic amounts. They essentially begin to suffocate the brain's communication network.

SPEAKER_01

Aaron Powell Okay, and this is where we need to give you the specific vocabulary. It's not just two proteins, is it?

SPEAKER_00

Correct. So the first protein is called amyloid beta. When it builds up too much, it forms these dense, sticky clusters outside the brain cells.

SPEAKER_01

And these are the famous plaques?

SPEAKER_00

These are the plaques. You can think of them like, I don't know, massive road construction that just completely jams up all the neural traffic.

SPEAKER_01

Okay, that's a clear image. And the second protein.

SPEAKER_00

The second is tau. And this one is different. It starts twisting into these abnormal fibers inside the brain cells, and that forms what we call neurofibrillary tangles.

SPEAKER_01

So if the plaques are traffic jam outside the cell.

SPEAKER_00

Then the tangles are internal structural damage. It's like the support beams of the cell twisting and buckling until the whole structure just collapses from within.

SPEAKER_01

Wow. So it's a physical traffic jam outside and a structural failure inside. That's devastating.

SPEAKER_00

That's the physical component, yes. But we also see a chemical problem. Our sources r really emphasize the role of acetylcholine.

SPEAKER_01

Which is a neurotransmitter.

SPEAKER_00

A critical one. It's basically the chemical messaging service between brain cells. In patients with AD, acetylcholine levels just plummet, which makes the communication failure from the plaques entangles even worse.

SPEAKER_01

Aaron Powell So you have a physical block and a chemical shortage.

Early To Late Symptoms

SPEAKER_00

Exactly. And the um the end result of that double whammy is that the brain cells themselves start to shrivel and eventually they die.

SPEAKER_01

Aaron Powell Before we track how this looks from the outside, the symptoms, let's just quickly touch on who is most susceptible. What does the research say about risk factors?

SPEAKER_00

Aaron Ross Powell The risk factors are uh pretty crucial for understanding the whole landscape. The biggest one, not surprisingly, is simply increasing age. The risk just climbs dramatically after 65.

SPEAKER_01

And there's a family connection?

SPEAKER_00

Strong one. Having a parent or a sibling with AD significantly raises your personal risk. And then finally, there are certain specific genetic factors you can inherit that just make you more vulnerable.

SPEAKER_01

Okay, so let's connect that internal biology to the outward experience. AD is progressive. The symptoms follow this, well, this distinct and often heartbreaking timeline. How do the sources break down the stages?

SPEAKER_00

We can draw a pretty clear line between the early stages, where a person can still be surprisingly independent, and the later, more debilitating stages.

SPEAKER_01

So what does that early phase look like?

SPEAKER_00

In the earliest phase, the challenges are almost all focused on acquiring new memories and trying to retain new information.

SPEAKER_01

So they might repeat stories or forget a conversation they just had?

SPEAKER_00

Precisely. Or struggle to learn a new recipe, something like that.

SPEAKER_01

So if they're forgetting what they had for breakfast, that's early stage. But they can still, say, button their own shirt.

SPEAKER_00

That is the crucial nuance right there. A person in early AD usually retains their ability to manage their daily physical needs. They can feed themselves, bathe, dress, groom, all without assistance.

SPEAKER_01

The operating system is failing, but the hardware, the motor functions, they're still working.

SPEAKER_00

A great way to put it. The basic self-care is still intact.

SPEAKER_01

So when does that change? When does the deterioration move into those middle and later stages?

SPEAKER_00

Aaron Powell That's when the brain's executive functions really begin to collapse. The loss shifts from just new memories to the gradual erasure of older, more distant memories.

SPEAKER_01

And this is where complex tasks become impossible.

SPEAKER_00

Exactly. Things that require planning in sequence: managing a budget, preparing a meal with multiple steps, or just remembering the sequence of taking daily medication.

SPEAKER_01

And I know a big one for caregivers is the loss of spatial awareness.

SPEAKER_00

It is a huge source of anxiety. The sources highlight the danger of losing your sense of direction, even in a place that's completely familiar, like your own neighborhood.

SPEAKER_01

Or even your own house.

SPEAKER_00

Yes, it's a profound loss of that internal map we all have.

SPEAKER_01

And beyond memory and function, the psychological and behavioral changes seem, I mean, they seem just as devastating.

SPEAKER_00

They often are for everyone involved. We frequently see personality changes, um, things like irritability, escalating anxiety, or really profound depression in the earlier phases.

SPEAKER_01

But it gets more severe.

SPEAKER_00

It does. As the disease moves into the middle and late stages, these symptoms can escalate pretty severely.

SPEAKER_01

We're talking about delusions and hallucinations here. That must be incredibly difficult to manage.

SPEAKER_00

Incredibly. Delusions are these irrational beliefs. A patient might sincerely believe someone is stealing from them or that they're being persecuted. Hallucinations are sensory experiences that just aren't real seeing or hearing things.

SPEAKER_01

And this can lead to things like aggression.

SPEAKER_00

It can, and it's often combined with a very dangerous tendency to wander away from home. It just requires immense, constant protective care.

Diagnosis And Look-Alikes

SPEAKER_01

Aaron Ross Powell That thought, that level of cognitive distress really brings home how difficult this diagnosis must be, which is where we should go now. Let's unpack this. The affected person often doesn't recognize there's a problem, right? They might even deny it.

SPEAKER_00

It's very common, yes.

SPEAKER_01

So how is a diagnosis of AD actually reached? It must rely so heavily on family and friends.

SPEAKER_00

It absolutely does. The diagnosis really relies on the history gathered from the people who see the person every day, the ones who can report on memory lapses, poor judgment, or personality changes. The family is the cornerstone.

SPEAKER_01

And the big challenge, which are sources stress, is that there is no single definitive test for Alzheimer's. You can't just get a blood test that gives you a yes or no.

SPEAKER_00

That is correct. The diagnosis is clinical. It's built on, well, on exclusion and compiled evidence. A doctor will start with a medical history, a physical and neurological exam, and what's called a mental status exam.

SPEAKER_01

Simple cognitive tests.

SPEAKER_00

Right. Simple tests involving visual tasks, writing, and memory checks.

SPEAKER_01

Aaron Powell But, and this feels like the most critical part of this section for anyone listening. Before a doctor even considers an irreversible diagnosis of AD, they have to rule out other conditions that can look just like it.

SPEAKER_00

This step is profoundly important. It is, frankly, the only chance for a truly treatable, reversible diagnosis.

SPEAKER_01

Aaron Powell And what's fascinating is that the sources pinpoint two specific conditions that can perfectly mimic AD symptoms.

SPEAKER_00

They can. And if they're caught, the outcome is completely different. We're talking about very low levels of vitamin B12 or a very underactive thyroid, also known as hypothyroidism.

SPEAKER_01

Wait, so a vitamin deficiency or a thyroid issue can cause cognitive decline severe enough that it looks like Alzheimer's?

SPEAKER_00

That is precisely the danger and also the hope. The incredibly important takeaway for you is that the memory and thinking problems from these issues can improve and even go away entirely with treatment.

SPEAKER_01

Wow. So if a doctor skips that step, those simple blood tests.

SPEAKER_00

They might unnecessarily doom a patient to an irreversible diagnosis when the real problem is entirely fixable.

SPEAKER_01

That makes the blood work just about the most important tool in the whole process. It's like checking the oil before you declare the engine is broken for good.

SPEAKER_00

A perfect analogy. So if those simple tests come back clean, but cognitive problems are still there, what's next?

SPEAKER_01

Right. What's the next step?

SPEAKER_00

They might move on to more detailed neuropsychological testing, which is a much deeper dive into cognition, and they'll almost certainly order brain imaging studies, a CT scan or an MRI.

SPEAKER_01

But it's vital to understand what these scans can and maybe more importantly, cannot do.

SPEAKER_00

Yes. They cannot diagnose AD with certainty.

SPEAKER_01

But they rule other things out.

SPEAKER_00

Exactly. They are critical for ruling out other structural causes, things like a brain tumor or evidence of a stroke. The scans can show brain shrinkage or atrophy, which supports a clinical diagnosis of AD, but it's still not definitive proof.

SPEAKER_01

And the diagnosis is usually confirmed by a specialist.

SPEAKER_00

Yes, after referral to a neurologist, a geriatrician, or maybe a geriatric psychiatrist.

SPEAKER_01

Aaron Powell So the picture is clear. AD is irreversible. Function declines until death. The goal has to shift entirely to management. What do the sources say about providing some hope, both in delaying the onset and slowing it down once it starts?

SPEAKER_00

Let's start with prevention, or maybe more accurately, delaying the onset of symptoms. The evidence we have strongly supports simple lifestyle factors that you can control right now.

SPEAKER_01

Like staying active.

SPEAKER_00

Staying physically and mentally active is key. Regular physical exercise, particularly aerobic exercise, seems to be very protective.

SPEAKER_01

And diet always comes up in these conversations.

Imaging And Specialist Referral

SPEAKER_00

He does. The sources specifically highlight a dietary pattern, kind of like a Mediterranean style. They emphasize a diet with plenty of fish, olive oil, and lots of vegetables.

SPEAKER_01

So this is about delaying onset and maybe slowing progression.

SPEAKER_00

It seems to be, yes. It just underscores that what's good for your heart and your vascular health is also really good for your brain.

SPEAKER_01

Okay, let's shift to treatment for those already diagnosed. What are the workhorse drugs that aim to slow the decline?

SPEAKER_00

For mild to moderate AD, we rely on a class of drugs called cholinesterase inhibitors. Now, since we said acetylcholine, the brain's messenger, is in short supply.

SPEAKER_01

Right.

SPEAKER_00

These drugs work by inhibiting the enzyme that breaks it down.

SPEAKER_01

So you're basically preserving what little of the messenger chemical is left.

SPEAKER_00

That's a great way to think about it. You're helping the brain make the most of its existing supply. For moderate to severe AD, there's also a drug called mementine, which works a bit differently to help stabilize memory.

SPEAKER_01

And now we have to talk about the newer, more complex therapies, the ones that have been all over the news. This is where we need to be cautiously optimistic. The monoclonal antibodies.

SPEAKER_00

We are. We're talking specifically about aducanimab, aduhelm, and the newer one, Lacanimab, um, Gipsula. Both got accelerated FDA approval.

SPEAKER_01

And unlike the other drugs that just manage symptoms, these are designed to attack the underlying problem.

Prevention And Lifestyle

SPEAKER_00

Exactly. They target and try to clear out those amyloid beta protein deposits we talked about earlier, the plaques.

SPEAKER_01

The hope being if you clear the plaques, you might slow or even halt the disease's progression. But the sources are very clear that we have to stress the caution around these drugs.

SPEAKER_00

We absolutely must. While they represent a huge leap forward in targeting the disease mechanism itself, they come with significant risks. The main concern is something called amylaid-related imaging abnormalities or ARAA.

SPEAKER_01

ARAA, and what is that?

SPEAKER_00

It refers to side effects you can see on brain scans, specifically brain swelling or microhemorrhages, tiny little bleeds in the brain.

SPEAKER_01

That sounds extremely serious.

SPEAKER_00

It is. Patients on these drugs have to be monitored with regular MRI scans to catch these things early. It really turns the treatment decision into a very careful risk versus reward calculation.

SPEAKER_01

So beyond the pharmaceuticals, supportive non-drug care is still absolutely essential.

SPEAKER_00

It's paramount. The supportive environment is everything. Caregivers need to maintain familiar surroundings, people, and routines. Too much change can trigger confusion and agitation.

SPEAKER_01

And creating safe environments to manage things like laundering.

SPEAKER_00

Critical. And also making sure the patient stays engaged, even as their abilities fade.

SPEAKER_01

Through things like music or art therapy.

SPEAKER_00

Precisely. Music, art, occupational therapy. They all provide essential stimulation and can offer real emotional outlets. It really takes a whole team.

SPEAKER_01

This deep dive has really given us a much clearer picture of AD from the biology of plaques and tangles all the way to the cutting edge of these new, if controversial, therapies.

SPEAKER_00

I hope so.

Current Medications Explained

SPEAKER_01

And I think most importantly, we've highlighted that critical need for a proper diagnosis, making sure to rule out treatable conditions like a B12 deficiency or thyroid issues before accepting that irreversible diagnosis.

SPEAKER_00

Alzheimer's remains a severe challenge, there's no doubt. But this kind of informed approach, combining lifestyle efforts, early and comprehensive diagnosis, and the uh the careful use of modern treatments, that offers the most critical path forward.

SPEAKER_01

And that leaves us with a final provocative thought for you to consider as you reflect on all this. If optimized lifestyle choices, physical and mental activity, diet, and exercise, are scientifically shown to delay the onset of symptoms and slow disease progression later in life, how much earlier in life does the compounding biological benefit of an optimized lifestyle truly begin? Something for you to mull over until our next deep dive.